MIRA Pharmaceuticals (NASDAQ:MIRA) Issues Quarterly Earnings Results, Beats Estimates By $0.14 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) released its earnings results on Friday. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14, Zacks reports.

MIRA Pharmaceuticals Stock Performance

NASDAQ:MIRA traded down $0.04 during trading hours on Friday, hitting $1.06. The company’s stock had a trading volume of 81,979 shares, compared to its average volume of 316,854. The company has a market capitalization of $17.55 million, a PE ratio of -1.89 and a beta of 2.31. The business’s 50-day moving average is $1.12 and its two-hundred day moving average is $1.23. MIRA Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $5.01.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.